ABBISKO-B (02256.HK) plans to issue in total 42.9 million shares by placement, with estimated net proceeds of HKD 517.3 million
NewTimeSpace News:ABBISKO-B (02256.HK) announced on Apr 21, 2026 that the company has entered into a placement agreement with the placement agent on Apr 21, 2026. According to the agreement, the placing agent conditionally agreed to use its best endeavors to procure placees to subscribe for in total 42.9 million shares placement, which represent approximately 6.3% of the company's existing issued share capital as of the date of this announcement, and approximately 5.92% after the subscription.
The placement price per share is HKD 12.18. The total proceeds from the placement are estimated to be about HKD 522.5 million. After deducting the placement commission, professional fees, and all related expenses that the company may incur, the net proceeds from the placement are estimated to be approximately HKD 517.3 million.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- ABBISKO-B (02256.HK): First patient dosed in Phase I trial of pan-KRAS inhibitor ABSK211, preclinically covering multiple KRAS alterations
- ABBISKO-B(02256.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 193.47 million, turned into a loss from a profit YoY
- ABBISKO-B (02256.HK): IND application of oral pan-KRAS inhibitor ABSK211 approved by NMPA
- ABBISKO-B (02256.HK): Oral Pan-KRAS Inhibitor ABSK211 Cleared by FDA for Phase I Trial in KRAS-Altered Solid Tumours
- ABBISKO-B(02256.HK): Positive Preliminary Phase II Data of ABSK061 Plus ABSK043 for FGFR2-Positive Advanced Gastric Cancer Released